A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute
- PMID: 7935701
- DOI: 10.1056/NEJM199411173312001
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute
Abstract
Background: Amphotericin B has long been the standard treatment for candidemia, but its use is complicated by its toxicity. More recently, fluconazole, a water-soluble triazole with activity against candida species and little toxicity, has become available. We conducted a multicenter randomized trial that compared amphotericin B with fluconazole as treatment for candidemia.
Methods: To be eligible, patients had to have a positive blood culture for candida species, a neutrophil count > or = 500 per cubic millimeter, and no major immunodeficiency. Patients were randomly assigned to receive either amphotericin B (0.5 to 0.6 mg per kilogram of body weight per day) or fluconazole (400 mg per day), each continued for at least 14 days after the last positive blood culture. Outcomes were assessed by a group of investigators blinded to treatment assignment.
Results: Of the 237 patients enrolled, 206 met all entry criteria. The most common diagnoses were renal failure, nonhematologic cancer, and gastrointestinal disease. There was no statistically significant difference in outcome: of the 103 patients treated with amphotericin B, 81 (79 percent) were judged to have been treated successfully, as were 72 of the 103 patients treated with fluconazole (70 percent P = 0.22; 95 percent confidence interval for the difference, -5 to 23 percent). The bloodstream infection failed to clear in 12 patients in the amphotericin group and 15 in the fluconazole group; the species most commonly associated with failure was Candida albicans. There were 41 deaths in the amphotericin group and 34 deaths in the fluconazole group (P = 0.20). Intravascular catheters appeared to be the most frequent source of candidemia. There was less toxicity with fluconazole than with amphotericin B.
Conclusions: In patients without neutropenia and without major immunodeficiency, fluconazole and amphotericin B are not significantly different in their effectiveness in treating candidemia.
Comment in
- ACP J Club. 1995 Mar-Apr;122(2):42
- 
  
  The treatment of candidemia.N Engl J Med. 1995 Apr 20;332(16):1100-1; author reply 1101-2. N Engl J Med. 1995. PMID: 7898536 No abstract available.
- 
  
  The treatment of candidemia.N Engl J Med. 1995 Apr 20;332(16):1101; author reply 1101-2. N Engl J Med. 1995. PMID: 7898537 No abstract available.
- 
  
  The treatment of candidemia.N Engl J Med. 1995 Apr 20;332(16):1101; author reply 1101-2. N Engl J Med. 1995. PMID: 7898538 No abstract available.
- 
  
  The treatment of candidemia.N Engl J Med. 1995 Apr 20;332(16):1101; author reply 1101-2. N Engl J Med. 1995. PMID: 7898539 No abstract available.
- 
  
  Management of candidemia.N Engl J Med. 1994 Nov 17;331(20):1371-2. doi: 10.1056/NEJM199411173312011. N Engl J Med. 1994. PMID: 7935710 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
- Full Text Sources
- Other Literature Sources
- Medical
- Miscellaneous
 
        